Moriah J Brier1, Dianne L Chambless2, Jinbo Chen3, Jun J Mao4. 1. Veterans Affairs Puget Sound Health Care System, USA. 2. University of Pennsylvania, USA. 3. Perelman School of Medicine at the University of Pennsylvania, USA. 4. Memorial-Sloan Kettering Cancer Center, USA. Electronic address: maoj@mskcc.org.
Abstract
PURPOSE: Aromatase inhibitors (AIs) are a potentially life-saving treatment for breast cancer survivors, yet poor adherence to treatment is a prevalent problem. A common adverse effect of AI treatment is arthralgia, which is identified by survivors as a major reason for treatment discontinuation. Women who experience arthralgia on AIs often report feeling they have aged rapidly while on the treatment. In the present study, we examined whether arthralgia-associated ageing perceptions predicted non-adherence. PATIENTS AND METHODS: We conducted a prospective cohort study among women with stage I-III breast cancer, who were on an AI and completed the Penn Arthralgia Aging Scale within 2 years of AI initiation. Adherence data were abstracted from medical charts by trained raters. Cox proportional hazard analysis was used to determine the relationship between ageing perceptions and time to non-adherence. All analyses included adjustments for joint pain severity. RESULTS: Among 509 participants, 144 (28.3%) were non-adherent. As hypothesised, women with high levels of ageing perceptions were at greater risk of non-adherence than women with low levels of ageing perceptions (adjusted hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.10-2.67; p = .02). High levels of depressive symptoms were also uniquely associated with increased risk of non-adherence (adjusted HR, 1.63; 95% CI, 1.03-2.59; p = .04). CONCLUSION: Perceptions of ageing related to arthralgia and depressive symptoms predicted non-adherence to AIs. These findings suggest that interventions that address negative beliefs about ageing due to AI-related arthralgia and depressive mood can potentially improve rates of adherence to AIs.
PURPOSE:Aromatase inhibitors (AIs) are a potentially life-saving treatment for breast cancer survivors, yet poor adherence to treatment is a prevalent problem. A common adverse effect of AI treatment is arthralgia, which is identified by survivors as a major reason for treatment discontinuation. Women who experience arthralgia on AIs often report feeling they have aged rapidly while on the treatment. In the present study, we examined whether arthralgia-associated ageing perceptions predicted non-adherence. PATIENTS AND METHODS: We conducted a prospective cohort study among women with stage I-III breast cancer, who were on an AI and completed the Penn Arthralgia Aging Scale within 2 years of AI initiation. Adherence data were abstracted from medical charts by trained raters. Cox proportional hazard analysis was used to determine the relationship between ageing perceptions and time to non-adherence. All analyses included adjustments for joint pain severity. RESULTS: Among 509 participants, 144 (28.3%) were non-adherent. As hypothesised, women with high levels of ageing perceptions were at greater risk of non-adherence than women with low levels of ageing perceptions (adjusted hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.10-2.67; p = .02). High levels of depressive symptoms were also uniquely associated with increased risk of non-adherence (adjusted HR, 1.63; 95% CI, 1.03-2.59; p = .04). CONCLUSION: Perceptions of ageing related to arthralgia and depressive symptoms predicted non-adherence to AIs. These findings suggest that interventions that address negative beliefs about ageing due to AI-related arthralgia and depressive mood can potentially improve rates of adherence to AIs.
Authors: Felipe B Schuch; Davy Vancampfort; Justin Richards; Simon Rosenbaum; Philip B Ward; Brendon Stubbs Journal: J Psychiatr Res Date: 2016-03-04 Impact factor: 4.791
Authors: P Hadji; V Ziller; J Kyvernitakis; M Bauer; G Haas; N Schmidt; K Kostev Journal: Breast Cancer Res Treat Date: 2013-01-20 Impact factor: 4.872
Authors: Kannie Chim; Sharon X Xie; Carrie T Stricker; Qing S Li; Robert Gross; John T Farrar; Angela DeMichele; Jun J Mao Journal: BMC Cancer Date: 2013-09-03 Impact factor: 4.430
Authors: A Laws; R Cheifetz; R Warburton; C E McGahan; J S Pao; U Kuusk; C Dingee; M L Quan; E McKevitt Journal: Curr Oncol Date: 2020-10-01 Impact factor: 3.677
Authors: Marina M Reeves; Caroline O Terranova; Elisabeth A H Winkler; Nicole McCarthy; Ingrid J Hickman; Robert S Ware; Sheleigh P Lawler; Elizabeth G Eakin; Wendy Demark-Wahnefried Journal: Nutrients Date: 2021-11-15 Impact factor: 5.717
Authors: Myriam Gagné; Sophie Lauzier; Martine Lemay; Carmen G Loiselle; Louise Provencher; Chantale Simard; Laurence Guillaumie Journal: Support Care Cancer Date: 2022-02-08 Impact factor: 3.359